Recent Drugs Hailed as a 'Pivotal Moment' in Combating Drug-Resistant Gonorrhea
The first new treatments for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the fight against superbug strains of the infection, according to researchers.
A Worldwide Health Concern
Gonorrhoea infections are on the rise around the world, with figures suggesting over 82 million infections per year. Notably increased rates are observed in Africa and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were triple the level compared to figures for 2014.
“The approval of novel therapies for gonorrhoea is an significant and necessary advancement in the face of rising global incidence, the spread of superbugs and the very limited therapeutic options currently available.”
Health officials are deeply concerned about the surge in antibiotic-resistant strains. The World Health Organization has classified it as a "critical concern". A tracking program showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.
Two New Therapies Gain Authorization
Zoliflodacin, marketed under the name a brand name, was authorized by the US FDA in recent days for use against gonorrhoea. This infection can lead to major issues, including the inability to conceive. Scientists hope that focused deployment of this new drug will help delay the spread of drug resistance.
Gepotidacin, developed by the drugmaker GSK, also received approval in close succession. This medication, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.
A Unique Partnership
This new treatment was the result of a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to see it through.
“This milestone represents a significant shift in the management of multidrug-resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”
Testing Outcomes and Worldwide Availability
Based on findings detailed in a major medical journal, the new drug eradicated more than 90% of uncomplicated infections. This establishes an comparable level with the existing first-line therapy, which combines two antibiotics. The study enrolled nearly 1,000 volunteers from several countries including the United States, Thailand, South Africa, and European nations.
As part of the agreement of its development partnership, GARDP has the authority to license and sell the drug in a wide range of regions with limited resources.
Doctors on the front lines have voiced optimism. The availability of a single-dose, oral treatment of this kind is hailed as a "critical tool" for managing the epidemic. This is deemed essential to reduce the burden of the disease for patients and to prevent the spread of untreatable gonorrhoea worldwide.
